Obesity management: Update on orlistat

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 817-821

  Drew, Belinda S ^a   Dixon, Andrew F ^a   Dixon, John B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Cholesterol; Diet; Hypertension; Obese; Orlistat; Weight

Indexed keywords

AMIODARONE; CALCIUM; CYCLOSPORIN; PLACEBO; TETRAHYDROLIPSTATIN; VITAMIN D; WARFARIN;

BLOATING; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON CANCER; COMORBIDITY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEFECATION URGENCY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FECES INCONTINENCE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEATORRHEA; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; COMORBIDITY; DRUG INTERACTIONS; HUMANS; LACTONES; OBESITY; PATIENT COMPLIANCE; WEIGHT LOSS;

EID: 38149123238     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Avenell A, Brown TJ, McGee MA, et al. 2004. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet, 17:317-35.
2. Chanoine JP, Hampl S, Jensen C, et al. 2005. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA, 293:2873-81
3. Dixon JB, O'Brien P. 2001. A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/ m(2). Int J Obes Relat Metab Disord, 25:793-7.
4. Dixon JB, O'Brien PE. 2002. Lipid profile in the severely obese: changes with weight loss after lap-band surgery. Obes Res, 10:903-10.
5. Douketis JD, Macie C, Thabane L, et al. 2005. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond), 29:1153-67.
6. Ferraz RR, Tiselius HG, Heilberg IP. 2004. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int, 66:676-82.
7. Finer N, James WP, Kopelman PG, et al. 2000. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord, 24:306-13.
8. Garcia SB, Barros LT, Turatti A, et al. 2006. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett, 240:221-4.
9. Goldstein DJ. 1992. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord, 16:397-415.
10. Gotfredsen A, Westergren Hendel H, Andersen T. 2001. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord, 25:1154-60.
11. Hauptman J. 2000. Orlistat: selective inhibition of caloric absorption can affect long-term body weight. Endocrine, 13:201-6.
12. Hutton B, Fergusson D. 2004. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr, 80:1461-8.
13. Knowler WC, Barrett-Connor E, Fowler SE, et al. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346:393-403.
14. Lacey LA, Wolf A, O'Shea D, et al. 2005. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond), 29:975-82.
15. Lindgarde F. 2000. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med, 248:245-54.
16. Maahs D, de Sema DG, Kolotkin RL, et al. 2006. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract, 12:18-28.
17. MacWalter RS, Fraser HW, Armstrong KM. 2003. Orlistat enhances warfarin effect. Ann Pharmacother, 37:510-12.
18. MeDuffie JR, Calis KA, Booth SL, et al. 2002. Effects of orlistal on fat-soluble vitamins in obese adolescents. Pharmacotherapy, 22:814-22.
19. McNeely W, Benfield P. 1998. Orlistat. Drugs, 56:241-9; discussion 250.
20. Mittendurfer B, Ostlund RE Jr, Patterson BW, et al. 2001. Orlistat inhibits dietary cholesterol absorption. Obes Res, 9:599-604.
21. Norris SL, Zhang X, Avenell A, et al. 2005. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev, (2): CD004095.
22. Norris SL, Zhang X, Avenell A, et al. 2005. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev, 1:CD004096.
23. Orlistat. 2007. Orlistat: drug information [online]. URL: http://uptodateonline.com.
24. Padwal R, Li SK, Lau DC. 2003. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev, 4:CD004094.
25. Padwal RS, Majumdar SR. 2007. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet, 369:71-7.
26. Richelsen B, Tonstad S, Rossner S, et al. 2007. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care, 30:27-32.
27. Singh A, Sarkar SR, Gaber LW, et al. 2007. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis, 49:153-7.
28. Sjostrom L, Rissanen A, Andersen T, et al. 1998. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients European Multicentre Orlistat Study Group. Lancet, 352:167-72.
29. Torgerson JS, Hauptman J, Boldrin MN, et al. 2004. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27:155-61.
30. Totoian ES, Frolova NG, Manasian AS, et al. 2006. [Use of orlistat (xenical) in the treatment of women with obesity and disorders of menstrual cycle]. Georgian Med News, 139:20-2.
31. Vray M, Joubert JM, Eschwege E, et al. 2005. [Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat]. Therapie, 60:17-24.
32. WHO. September 2006. WHO. Obesity and overweight fact sheet. September 2006. http://www.who.int/dietphysicalactivity/publications/facts/obesity/ en/. Volume, DOI:
33. Zelber-Sagi S, Kessler A, Brazowsky E, et al. 2006, A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 4:639-44.
34. Zhi J, Melia AT, Guerciolini R, et al. 1994. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther, 56:82-5.
35. Zhi J, Moore R, Kanitra L, et al. 2002. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol, 42:1011-19.
36. Zhi J, Moore R, Kanitra L, et al. 2003. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol, 43:428-35.